Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical


Infusion set creator Capillary Biomedical has been acquired by Tandem Diabetes Care, Inc., a global provider of insulin administration and diabetes technologies.

“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system”, “Through this acquisition, and through our efforts with existing infusion set partners, we look forward to developing new and innovative infusion set solutions that are designed to extend wear time and enhance user experience, while reducing occlusions, body burden and waste.”

John Sheridan, Tandem Diabetes Care president and chief executive officer

The original extended wear infusion set technology from Capillary Biomedical is still being developed and is not yet on the market. Financial details weren’t made public.

Tandem Diabetes Care, Inc., a San Diego, California-based firm that specialises in diabetes technology and insulin delivery, opens up new opportunities for people with diabetes, their loved ones, and healthcare professionals. With a human-centered design, development, and support process, the business creates cutting-edge goods and services for insulin users. The t:slim X2 insulin pump from Tandem features Control-IQ technology.

Next Post

ILC Dover announces the European launch of the Sentinel Clear XE™ PAPR

Sentinel Clear XETM Active Air Purifying Respirator (PAPR), a product of ILC Dover Inc., a company that specialises in novel single-use solutions for biotherapeutic and pharmaceutical processing worldwide and personal protective equipment (PPE), has been introduced in Europe. The device is perfect for shielding employees in pharmaceutical manufacturing facilities from […]